Equillium, Inc. (EQ)
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124, a microRNA implicated in inflammatory disease biology.
Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC
Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial initiation targeted for mid-2026. Company's Multi-Cytokine Platform enables selective cytokine targeting, aiming to improve efficacy and safety over broad-spectrum inhibitors like JAK/STAT signaling pathways. EQ302, an oral IL-15/IL-21 inhibitor for celiac disease, is positioned for partnering, offering potential future catalysts but remains in early discovery.
Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript
Equillium, Inc. ( EQ ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases November 5, 2025 12:00 PM EST Company Participants Bruce Steel - Co-Founder, CEO & Director Stephen Connelly - Chief Scientific Officer & President Francisco Quintana Brian Gordon Feagan Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Cha Cha Yang - Jefferies LLC, Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Brian Feagan Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Min Lee - Guggenheim Securities, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Equillium Bio Virtual KOL Event.
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Equillium (EQ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients
Equillium, Inc. EQ released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host disease (aGVHD).
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now
Equillium (EQ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Equillium (EQ) Upgraded to Buy: Here's What You Should Know
Equillium (EQ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock
Equillium (EQ) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth
Equillium (EQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
Equillium, Inc. (EQ) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to loss of $0.10 per share a year ago.
